for the tricuspid valve
StarTric
For more patients, for longer lives.
Developing a next generation transcatheter device, designed for the complexities of the tricuspid heart valve – to expand tricuspid regurgitation treatment.
for the Tricuspid valve
StarTric
For more patients, for longer lives.
Developing a next generation transcatheter device, designed for the complexities of the tricuspid heart valve – to expand tricuspid regurgitation treatment.
the first clover teer device
For more patients.
StarTric is developing a next generation Transcatheter Edge-to-Edge Repair (TEER) device for the treatment of Tricuspid Regurgitation (TR).
We are pioneering the first transcatheter device for a clover-shaped repair: a minimally invasive technology designed to standardize the proven surgical Clover technique to address most tricuspid heart valve anatomies.
With TriClover, StarTric aims to establish a new standard of care to treat a large population of patients with TR.
the medical need
Most TR patients go untreated.
TR is a serious, life-threatening condition: the vast majority of patients remain untreated, yet most of them die within five years of diagnosis.
3%
patients treated with surgery
Most patients are too fragile to undergo open-heart procedures.
Few
patients treated with Transcatheter
Current devices are not indicated for many patient anatomies.
Millions
patients without effective options
Most patients cannot be treated with existing therapeutic options.
designed for more patients
TriClover™
TriClover is a next-generation TEER device: the only technology based on the Clover technique, specifically designed for the tricuspid valve.
TriClover standardizes the proven tricuspid surgical procedure Clover, which is effective in most tricuspid valve anatomies.
Adaptable to most anatomies — independently of leaflet number and tethering.
Standardized procedure — a single device and a standardized sequence, conceived for ease of use.
Rooted in science — the surgical Clover approach is backed by up to 25 years of clinical practice.
The startric team
Co-founded by the surgeons who pioneered the Clover.
StarTric is led by an experienced executive team and co-founded by Prof. Ottavio Alfieri and Prof. Michele De Bonis — the cardiac surgeons who pioneered the Clover technique in tricuspid surgery and the Alfieri stitch for the mitral valve.
Backed by NLC Health Ventures and by the EU EIC Accelerator, among other investors.
Follow our journey.
Stay close to the milestones, the science, and the people behind TriClover — or get in touch to learn more.